Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q2CR
|
|||
| Former ID |
DNC014004
|
|||
| Drug Name |
1-(1,3,4-Oxadiazol-2-yl)-7-phenylheptan-1-one
|
|||
| Synonyms |
CHEMBL467796; 1-(1,3,4-Oxadiazol-2-yl)-7-phenylheptan-1-one; SCHEMBL2161990
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H18N2O2
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)CCCCCCC(=O)C2=NN=CO2
|
|||
| InChI |
1S/C15H18N2O2/c18-14(15-17-16-12-19-15)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2
|
|||
| InChIKey |
SRGOKBDAYNCSOV-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fatty acid amide hydrolase (FAAH) | Target Info | Inhibitor | [1] |
| BioCyc | Anandamide degradation | |||
| KEGG Pathway | Retrograde endocannabinoid signaling | |||
| Panther Pathway | Anandamide degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.